Global Isovaleric Acidemia (IVA) Treatment Market 2025–2029: Competitive Insights and Opportunities
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Isovaleric Acidemia (IVA) Treatment Industry Expected To Reach By 2029, Starting From 2025 Levels?
The isovaleric acidemia (IVA) treatment market has experienced robust expansion over the past few years. This market is projected to expand from $0.6 billion in 2024 to $0.63 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.5%. Historically, this growth has been driven by several factors, including heightened awareness of rare metabolic disorders, an increase in newborn screening initiatives, enhanced government funding for orphan diseases, a greater emphasis on enzyme replacement therapies, and a growing need for timely diagnosis and genetic counseling services.
The isovaleric acidemia (IVA) treatment market is projected to experience substantial growth in the upcoming years, with an anticipated rise to $0.79 billion by 2029, showcasing a compound annual growth rate (CAGR) of 5.8%. This expansion during the forecast period is driven by the growing adoption of gene therapy approaches, increased investment in rare disease research, an expanding pipeline of novel treatment options, rising collaborations between biotech firms and research institutes, and a heightened focus on personalized medicine for metabolic disorders. Key trends expected in this period include advancements in genetic testing technologies, sophisticated drug delivery systems for metabolic therapies, innovations in enzyme replacement formulations, the development of targeted gene editing tools, and improvements in newborn screening methodologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24269&type=smp
Which Drivers Are Shaping The Isovaleric Acidemia (IVA) Treatment Industry’s Market Share?
The increasing occurrence of metabolic disorders is projected to boost the expansion of the isovaleric acidemia (IVA) treatment market moving forward. Metabolic disorders are conditions that disrupt the body’s normal metabolic processes, thereby affecting how food is converted into energy. Common examples of these disorders include diabetes mellitus, hypothyroidism, hyperthyroidism, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), isovaleric acidemia (IVA), Gaucher disease, Fabry disease, Wilson’s disease, and various lysosomal storage disorders. The rise in metabolic disorder prevalence is often attributed to lifestyle factors such as poor diet and physical inactivity, which contribute to conditions like obesity and insulin resistance. Isovaleric acidemia treatment aids in managing metabolic disorders by addressing the buildup of toxic substances within the body, restoring typical metabolic function, and preventing potential complications like neurological damage. For instance, in November 2023, the American Diabetes Association, a US-based non-profit organization, reported that in 2022, around 25.5 million people in the U.S. were diagnosed with diabetes, making up 7.6% of the total population. Thus, the escalating prevalence of metabolic disorders serves as a significant driver for the growth of the isovaleric acidemia (IVA) treatment market.
What Are The Major Segments Identified In The Isovaleric Acidemia (IVA) Treatment Market?
The isovaleric acidemia (iva) treatment market covered in this report is segmented –
1) By Type: Classical Isovaleric Acidemia, Moderate Isovaleric Acidemia, Non-classical Isovaleric Acidemia
2) By Treatment: Dietary Management, Enzyme Replacement Therapy, Gene Therapy, Pharmacological Treatment
3) By Route of Administration: Oral, Injectable
4)By End-user: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Classical Isovaleric Acidemia: Dietary Management, Carnitine Supplementation, Glycine Supplementation, Emergency Management, Gene Therapy (Investigational)
2) By Non-classical Isovaleric Acidemia: Observation and Preventive Care, Mild Dietary Modifications, Occasional Supplementation, Genetic Counseling and Monitoring
3) By Moderate Isovaleric Acidemia: Protein-restricted Diet, Intermittent Carnitine/Glycine Therapy, Periodic Monitoring and Supportive Care, Acute Episode Management
Who Are The Key Multinational Companies Dominating The Isovaleric Acidemia (IVA) Treatment Market?
Major companies operating in the isovaleric acidemia (IVA) treatment market are Nestlé Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
Download The Full Report For Exclusive Market Findings:
How Does The Isovaleric Acidemia (IVA) Treatment Market Perform Across Key Geographic Regions?
North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isovaleric acidemia (IVA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Isovaleric Acidemia (IVA) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24269&type=smp
Browse Through More Reports Similar to the Global Isovaleric Acidemia (IVA) Treatment Market 2025, By The Business Research Company
Pharmaceutical Drugs And Biologics Logistics Market 2025
Cardiometabolic Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Comprehensive Metabolic Panel Cmp Testing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
